Optical Coherence Tomography Findings and Visual Outcome after Treatment with Intravitreal Bevacizumab in Parafoveal Telangiectasia

Methods: A prospective interventional study of 40 patients (80 eyes) with bilateral parafoveal telengectiasis. They were divided into three groups. Group 1 which included 15 patients with PFT were under observation and treated conservatively. Group 2 included 14 patients with PFT complicated by cystoid macular oedema who were treated with intravitreal injection of bevacizumab each (0.1 ml) under aseptic conditions. Group 3 included 11 patients with PFT and choroidal neovascular membranes who were treated with intravitreal injections of bevacizumab. In the three groups pre interventional and post interventional visual acuities were recorded. Pre and post intervention macular thickness was recorded by optical coherence tomography (OCT).Results: In group 1 mean vision at presentation was 0.264 ± 0.14decimals which was exactly the same as the mean vision (0.264 ± 0.14) after three months. The mean macular thickness was the same before and after three months. In Group 2 the mean vision at presentation was 0.19 (approx 6/18) significantly improved to 0.256 (6/12) ± 0.096 following bevacizumab injection. The mean macular thickness at presentation was 360.73 ± 43.22µ which showed significant decrease to 253.45 ± 32.6µ following the injection. In Group 3 the mean vision at presentation was 0.13(approx 6/60) ± 0.08 decimals after bevacizumab injection was 0.15 (6/36) ± 0.07 the difference was not statistically significant. The mean macular thickness at presentation was 469.17 ± 89.6µ which showed a significant decrease to 310.78±85.61µ following the injection. Conclusion: In patients with parafoveal telengiectasis alone the mean visual acuity and mean macular thickness are better than in patients with PFT complicated with CME and choroidal neovascular membranes. In patients with PFT complicated by CME there is definite short term improvement in visual acuity and in macular thickness following injection of bevacizumab.In patients with PFT complicated by CNVM there is definitely short term improvement in macular thickness but not in visual acuity following intravitreal injection of bevacizumab.

Methods: A prospective interventional study of 40 patients (80 eyes) with bilateral parafoveal telengectiasis. They were divided into three groups. Group 1 which included 15 patients with PFT were under observation and treated conservatively. Group 2 included 14 patients with PFT complicated by cystoid macular oedema who were treated with intravitreal injection of bevacizumab each (0.1 ml) under aseptic conditions. Group 3 included 11 patients with PFT and choroidal neovascular membranes who were treated with intravitreal injections of bevacizumab. In the three groups pre interventional and post interventional visual acuities were recorded. Pre and post intervention macular thickness was recorded by optical coherence tomography (OCT).Results: In group 1 mean vision at presentation was 0.264 ± 0.14decimals which was exactly the same as the mean vision (0.264 ± 0.14) after three months. The mean macular thickness was the same before and after three months. In Group 2 the mean vision at presentation was 0.19 (approx 6/18) significantly improved to 0.256 (6/12) ± 0.096 following bevacizumab injection. The mean macular thickness at presentation was 360.73 ± 43.22µ which showed significant decrease to 253.45 ± 32.6µ following the injection. In Group 3 the mean vision at presentation was 0.13(approx 6/60) ± 0.08 decimals after bevacizumab injection was 0.15 (6/36) ± 0.07 the difference was not statistically significant. The mean macular thickness at presentation was 469.17 ± 89.6µ which showed a significant decrease to 310.78±85.61µ following the injection. Conclusion: In patients with parafoveal telengiectasis alone the mean visual acuity and mean macular thickness are better than in patients with PFT complicated with CME and choroidal neovascular membranes. In patients with PFT complicated by CME there is definite short term improvement in visual acuity and in macular thickness following injection of bevacizumab.In patients with PFT complicated by CNVM there is definitely short term improvement in macular thickness but not in visual acuity following intravitreal injection of bevacizumab.